- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Fr | GE Healthcare looks to bring MediView's AR headsets to X-ray-guided surgeries | ||
| Fr | BD finds cybersecurity flaw that could allow hackers to disable infusion pumps | ||
| Fr | Vaxxinity will push for approval of COVID booster despite failing to beat Pfizer's competitor | ||
| Fr | Medtronic's HeartWare pump racks up another safety alert, this time for jammed driveline covers | ||
| Fr | Beam jumps back into off-the-shelf CAR-T race after FDA lifts clinical hold | ||
| Fr | Mirati's sitravatinib yet to improve survival at interim phase 3 cancer review, pushing back approval plan | ||
| Fr | 'Not convincing enough': Theratechnologies halts lead cancer trial over efficacy concerns | ||
| Fr | No surprises for Y-mAbs as FDA rejects rare pediatric cancer drug after AdComm savaging | ||
| Do | With gas shortages looming, Philips inks magnet research pact to make MRI scanners helium-free | ||
| Do | Elon Musk claims Neuralink is 6 months from implanting brain-computer interfaces in humans-and one day, he'll be one of them | ||
| Do | Roche thins Alzheimer's program after phase 3 failure, may seek 'external partnerships' | ||
| Do | SQZ CEO exits as biotech axes 60% staff; Synlogic succumbs to layoff pressure | ||
| Do | Titan Medical eyeing possible sale, merger amid threat of Nasdaq delisting | ||
| Do | Cancer-focused Liminatus sets out to test SPAC waters | ||
| Do | Pfizer, Roivant team up for new inflammatory-focused Vant-and no, they're not calling it Pfvant | ||
| Do | Rallybio revs up antibody discovery activities with risk-sharing AbCellera pact | ||
| Do | Pfizer-Valneva's Lyme vaccine triggers 6-month antibody response, validating phase 3 regimen | ||
| Mi | Advanced Clinical names Karra as VP of oncology unit | ||
| Mi | Vial reels in $67M in series B fund raising; adds NEXT Oncology to network | ||
| Mi | Deep learning AI could predict heart disease death from a chest X-ray 10 years out: study | ||
| Mi | Oncorus drops HSV solid tumor prospect, lays off 15% of workforce | ||
| Mi | Fresh off layoffs, X4 scores a phase 3 win for immune deficiency disorder drug | ||
| Mi | J&J's Ethicon, CMR Surgical pair up on minimally invasive robotic surgery | ||
| Mi | J&J unit, happy with AC Immune's progress on Alzheimer's vaccine, moves development to next step | ||
| Mi | Enzyme engineers Codexis cut short several programs, lay off 18% of staff |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
